Hosted on MSN25m
Zenas BioPharma initiated with an Outperform at Wolfe ResearchWolfe Research initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $19 price target After its IPO in September 2024, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback